Skip to main content
Premium Trial:

Request an Annual Quote

Bank Upgrades Sigma-Aldrich Stock

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment bank Robert W. Baird has upped its rating on Sigma-Aldrich's stock to "outperform" from "neutral," a day after the firm beat Wall Street expectations for fourth-quarter revenues and net income.

The St. Louis-based chemicals and research tools provider reported 12 percent revenue growth year over year to $572.5 million, beating analysts' consensus estimate of $561 million. The company also said that it expects 2010 organic revenue growth in the mid-single digits.

Baird Analyst Quintin Lai said the he expects Sigma-Aldrich to report revenue growth of around 6 percent to $2.29 billion. Analysts, on average, expect the firm to report revenues of $2.31 billion.

Lai placed a price target of $60 per share on Sigma-Aldrich's stock.

In mid-afternoon trade Thursday on the Nasdaq, shares of the firm were up 2 percent at $49.21.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.